BIO Investor Forum 2010 Presenter Profiles

SAN FRANCISCO--(BUSINESS WIRE)-- The BIO Investor Forum 2010 takes place Oct. 5 – 6, 2010 at the Palace Hotel in San Francisco.

Business Wire is the official newswire for the Forum. Breaking news releases, IR Kits, and webcast advisories are available at TradeshowNews.com, Business Wire's trade show, conference, and event news resource.

Listed below are BIO Investor Forum 2010 presenter profiles.

Company: Catena Pharmaceuticals, Inc.
Investor Relations Contact: Ian J. Mehr, President
Investor Relations Contact Phone: 919-806-4480
Web:

www.catenapharma.com

Date of Presentation: Tuesday, October 5, 10:30 am
Proliferative diseases such as cancer and fibrosis remain areas of high unmet medical need, creating intense suffering and major economic costs on the healthcare system. Catena Pharmaceuticals’s proprietary compounds have demonstrated a unique ability to aggressively fight damaging cell proliferation that leads to disease in animal models. Catena’s lead, VPC51299, antagonizes a subset of G-protein coupled receptors specific for lysophosphatidic acid (LPA), chemical in the body that promotes ovarian cancer tumor growth, and has been strongly implicated in organ fibrosis. Catena seeks a Series A financing round to advance VPC51299 towards human clinical trials.
 
 
Company: ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange: ZIOP (NASDAQ)
Investor Relations Contact: Tyler Cook
Investor Relations Contact Phone: 617-259-1982
Web:

www.ziopharm.com

Date of Presentation: 10/5/2010
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse, portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous (“IV”) and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world.
 

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 31 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.



CONTACT:

Business Wire
Global Event Services
310-820-9473
http://www.businesswire.com
http://www.tradeshownews.com
twitter: @tradeshownews
facebook: http://www.facebook.com/TradeshowNews

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.